Please login to the form below
ledipasvir
This page shows the latest ledipasvir news and features for those working in and with pharma, biotech and healthcare.
AbbVie sues NHS England over hep C procurement
treatment – as well as follow-up combinations such as Harvoni (sofosbuvir/ledipasvir) as well as Epclusa (sofosbuvir/velpatasvir) that was effective against all HCV genotypes.
Latest news
-
Gilead wins European approval for triple hep C combination Vosevi
The EC also approved an extension for Harvoni (ledipasvir/sofobuvir), - which was previously authorised to treat adults with chronic HCV genotypes 1, 3, 4, 5, or 6 - and will now include
-
Merck & Co pulls out of hepatitis C R&D as market shrinks
In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half
-
Gilead makes $11.9bn play for CAR-T specialist Kite
Gilead's deal comes as it faces a sharp slowdown in sales of its HCV therapies - led by Harvoni (sofosbuvir and ledipasvir) and Sovaldi (sofosbuvir) - which has led investors to call
-
Gilead gets OK for three-in-one hep C therapy in US
Other NS5A inhibitors on the market for HCV include Gilead's ledipasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and Merck &Co's elbasvir.
-
Samsung Bioepis wins CHMP nod for second Humira biosimilar
Both were reviewed under the accelerated assessment protocol because despite the robust efficacy of current drugs such as Gilead's Harvoni (sofosbuvir/ledipasvir) and AbbVie's Viekira (ombitasvir/paritaprevir/ritonavir and
More from news
Approximately 4 fully matching, plus 62 partially matching documents found.
Latest Intelligence
-
AbbVie: New firm, new thinking
Gilead Sciences has emerged as the leader in this field with Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), both of which have already made billions of dollars.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Manager- Healthcare Advertising
-
Negotiable
- CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...
-
EXCELLENT DAY RATES AVAILABLE
-
Associate Director
-
£75, 000-90, 000
- Business Development Director – Health Education
-
excellent commission
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Principal Health Economist - North-West
-
Negotiable
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Medical (Scientific) Director
-
£120, 000 benefits
-
Business Director
-
Competitive Salary Offered
-
Account Manager
-
Negotiable
-
Experienced Medical Writers
-
Competitive Salary and Benefits
-
Account Manager / Account Director
-
Competative
-
Medical Writer
-
Bonus Scheme, PTO &Private Healthcare
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
Subscribe to our email news alerts
- Blue Latitude Health joins Fishawack Group of Companies
- Clark Health Communications to bring AI to the forefront with new deal
- Merck exec steps down, two takes his place
- NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done
- FDA takes aim at pharma’s biosimilar-delaying tactics
- Circassia seeks shift to AIM after failing LSE criteria
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- Report: Achieving launch excellence in the challenging healthcare markets of today
- Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
- What is blockchain and why should i care - Richard Springham
- Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
- NHS medicines optimisation milestone
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Quick links
Infographics
